XPEP Exosome Mass Spec sample prep kit
- Known as:
- XPEP Exosome Mass Spec sample preparation kit reagent
- Catalog number:
- xpep100a-1
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Sbi systeme bioscience
- Gene target:
- XPEP Exosome Mass Spec sample prep kit
Related genes to: XPEP Exosome Mass Spec sample prep kit
- Gene:
- PREP NIH gene
- Name:
- prolyl endopeptidase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-03-12
- Date modifiied:
- 2016-10-05
Related products to: XPEP Exosome Mass Spec sample prep kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit(1-Kit) 14,15-EET_DHET Hypertension ELISA Kit Related articles to: XPEP Exosome Mass Spec sample prep kit
- Evaluation of the efficacy of immunotherapeutic strategies aimed at achieving durable antiretroviral treatment (ART)-free control within a clinical trial relies on analytical treatment interruptions (ATIs). ATIs involve stopping ART to assess post-intervention efficacy with frequent viral load monitoring. These trials rely on participant commitment but also involve uncertainty about the timing and experience of viral rebound, transmission risk, and impacts on personal and sexual relationships. Understanding participants' lived experiences is critical to participant involvement and retention and to designing ATI studies that are ethical, feasible, and acceptable. - Source: PubMed
Publication date: 2026/10/02
Gohil JesalMolina MarcelinoAhmed AliCollins SimonLee Ming JieElliott TamaraWhitlock GaryBoffito MartaGodakandaarachi PiyumikaFox JulieClarke AmandaKinloch-de Loes SabinePett SarahUriel AlisonMangawa IrvineRing KyleOrkin ChloeSutherland RebeccaHamzah LisaCicconi PaolaFrater JohnGrundy-Bowers MatthewDubé KarineFidler Sarah - Despite high risk of HIV infection, uptake of pre-exposure prophylaxis (PrEP) remains limited among male and transgender sex workers (MSW and TSW), and data on tailored interventions to improve access are scarce. The Nightcafé programme addresses this gap by offering low-threshold PrEP provision in a community-centred setting. This study assessed the programme's uptake, clinical feasibility and subsequent engagement in PrEP care. - Source: PubMed
Publication date: 2026/10/01
Heizmann ElenaFarnham AndreaGrolimund ChristianReal Jorge FloresHalm PaulBraig VeronikaKomaromi HadrienLaffers Giulietta MilaFehr JanHampel Benjamin - Dry eye disease (DED) affects visual function and quality of life. In Gaza, conflict, displacement, environmental exposure, and psychological distress may increase risk, but evidence is limited. This study estimated DED symptom prevalence among adults aged ≥40 years and examined associated factors. - Source: PubMed
Publication date: 2026/10/02
Aljarousha MohammedChe Azemin Mohd ZulfaezalBeshtawi Ithar MBadarudin Noor EzailinaIrfan BilalAbdu MustafaShaqoura Emad I HFeisal Nur Azalina SuziantiAbuhamad Asmaa YRahmat Baqiatu'l Sabiqi 'AssfiKaderi Mohd ArifinTawfik MohamedQazi Omair MuhammadAttaallah Sara - The purification of industrial enzymes typically relies on costly, multi‑step chromatographic protocols. To address this, we developed a novel platform termed Coated Bacterial Enzymes (CBEs), which enables one‑step purification and immobilization of recombinant proteins fused to the SlpA cell wall binding domain. As a proof of concept, we used a β‑galactosidase from of dairy relevance. The chimeric enzyme BbgII‑SlpA was expressed in and captured from crude lysate onto glutaraldehyde‑inactivated cells via SlpA domain. Binding was characterized by a dissociation constant (K) of 16.2 μM and maximum binding capacity (B) of 144 μmol/g. The resulting CBEs biocatalyst exhibited optimal activity at pH 6.0 for ONPG and lactose, with a broader pH profile than the free enzyme. Optimal temperatures were 60 °C for ONPG and 50 °C for lactose, and CBEs retained >80% activity after 390 min at 45 °C, compared to 20% for the free enzyme. Catalytic efficiencies (kcat/Km) were 2.62 × 10 M·s for ONPG and 4.40 × 10 M·s for lactose. Moreover, CBEs showed improved tolerance to cations such as Ca and Fe. Furthermore, at 7 °C in skim milk, the CBEs achieved approximately 53% lactose hydrolysis within 20 h and retained 35-45% of its initial activity after five reuse cycles. - Source: PubMed
Publication date: 2026/10/01
Harguindeguy InésHomse Melisa SRamírez Andrea CSabetta Alan ECavalitto Sebastián FOrtiz Gastón E - Chatbots have the potential to reduce barriers to preexposure prophylaxis (PrEP), including lack of awareness, misconceptions, and stigma, by providing anonymous and continuous support. However, in the context of PrEP, chatbots are still nascent; they lack personalized informational expertise, peer experiential expertise, and human-like emotional support to facilitate future PrEP uptake. These personalized and relatable forms of support are crucial for increasing engagement, influencing health decisions, and fostering resilience and well-being. - Source: PubMed
Publication date: 2026/10/01
Sayed FatimaPark AlbertSullivan Patrick SeanGe Yaorong